The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies

Angela Kwok-Fung Lo; Christopher W. Dawson; Hong Lok Lung; Ka-Leung Wong; Lawrence S. Young

doi:10.3390/cancers12071940

The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies

Angela Kwok-Fung Lo
, Christopher W. Dawson
, Hong Lok Lung
, Ka-Leung Wong^*
, Lawrence S. Young^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

18 Citations (Scopus)

2 Downloads (CityUHK Scholars)

Abstract

Epstein-Barr virus (EBV) is closely linked to the development of a number of human cancers. EBV-associated malignancies are characterized by a restricted pattern of viral latent protein expression which is sufficient for the virus to both initiate and sustain cell growth and to protect virus-infected cells from immune attack. Expression of these EBV proteins in malignant cells provides an attractive target for therapeutic intervention. Among the viral proteins expressed in the EBV-associated epithelial malignancies, the protein encoded by the BamHI-A rightward frame 1 (BARF1) is of particular interest. BARF1 is a viral oncoprotein selectively expressed in latently infected epithelial cancers, nasopharyngeal carcinoma (NPC) and EBV-positive gastric cancer (EBV-GC). Here, we review the roles of BARF1 in oncogenesis and immunomodulation. We also discuss potential strategies for targeting the BARF1 protein as a novel therapy for EBV-driven epithelial cancers. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Original language	English
Article number	1940
Number of pages	12
Journal	Cancers
Volume	12
Issue number	7
Online published	17 Jul 2020
DOIs	https://doi.org/10.3390/cancers12071940
Publication status	Published - Jul 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Keywords

BARF1
EBV
EBV-associated cancers
Immunotherapy
Peptide therapy

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Access Output

10.3390/cancers12071940

422769832.pdfFinal Published version, 881 KBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{efd2cc6f5e7f4f62a3f26c32e9f9b5cf,

title = "The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies",

abstract = "Epstein-Barr virus (EBV) is closely linked to the development of a number of human cancers. EBV-associated malignancies are characterized by a restricted pattern of viral latent protein expression which is sufficient for the virus to both initiate and sustain cell growth and to protect virus-infected cells from immune attack. Expression of these EBV proteins in malignant cells provides an attractive target for therapeutic intervention. Among the viral proteins expressed in the EBV-associated epithelial malignancies, the protein encoded by the BamHI-A rightward frame 1 (BARF1) is of particular interest. BARF1 is a viral oncoprotein selectively expressed in latently infected epithelial cancers, nasopharyngeal carcinoma (NPC) and EBV-positive gastric cancer (EBV-GC). Here, we review the roles of BARF1 in oncogenesis and immunomodulation. We also discuss potential strategies for targeting the BARF1 protein as a novel therapy for EBV-driven epithelial cancers. {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

keywords = "BARF1, EBV, EBV-associated cancers, Immunotherapy, Peptide therapy",

author = "Lo, \{Angela Kwok-Fung\} and Dawson, \{Christopher W.\} and Lung, \{Hong Lok\} and Ka-Leung Wong and Young, \{Lawrence S.\}",

year = "2020",

month = jul,

doi = "10.3390/cancers12071940",

language = "English",

volume = "12",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies

AU - Lo, Angela Kwok-Fung

AU - Dawson, Christopher W.

AU - Lung, Hong Lok

AU - Wong, Ka-Leung

AU - Young, Lawrence S.

PY - 2020/7

Y1 - 2020/7

N2 - Epstein-Barr virus (EBV) is closely linked to the development of a number of human cancers. EBV-associated malignancies are characterized by a restricted pattern of viral latent protein expression which is sufficient for the virus to both initiate and sustain cell growth and to protect virus-infected cells from immune attack. Expression of these EBV proteins in malignant cells provides an attractive target for therapeutic intervention. Among the viral proteins expressed in the EBV-associated epithelial malignancies, the protein encoded by the BamHI-A rightward frame 1 (BARF1) is of particular interest. BARF1 is a viral oncoprotein selectively expressed in latently infected epithelial cancers, nasopharyngeal carcinoma (NPC) and EBV-positive gastric cancer (EBV-GC). Here, we review the roles of BARF1 in oncogenesis and immunomodulation. We also discuss potential strategies for targeting the BARF1 protein as a novel therapy for EBV-driven epithelial cancers. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

AB - Epstein-Barr virus (EBV) is closely linked to the development of a number of human cancers. EBV-associated malignancies are characterized by a restricted pattern of viral latent protein expression which is sufficient for the virus to both initiate and sustain cell growth and to protect virus-infected cells from immune attack. Expression of these EBV proteins in malignant cells provides an attractive target for therapeutic intervention. Among the viral proteins expressed in the EBV-associated epithelial malignancies, the protein encoded by the BamHI-A rightward frame 1 (BARF1) is of particular interest. BARF1 is a viral oncoprotein selectively expressed in latently infected epithelial cancers, nasopharyngeal carcinoma (NPC) and EBV-positive gastric cancer (EBV-GC). Here, we review the roles of BARF1 in oncogenesis and immunomodulation. We also discuss potential strategies for targeting the BARF1 protein as a novel therapy for EBV-driven epithelial cancers. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

KW - BARF1

KW - EBV

KW - EBV-associated cancers

KW - Immunotherapy

KW - Peptide therapy

UR - https://www.scopus.com/pages/publications/85088496386

UR - https://www.scopus.com/pages/publications/85088496386#tab=impact

U2 - 10.3390/cancers12071940

DO - 10.3390/cancers12071940

M3 - RGC 21 - Publication in refereed journal

SN - 2072-6694

VL - 12

JO - Cancers

JF - Cancers

IS - 7

M1 - 1940

ER -

The Therapeutic Potential of Targeting BARF1 in EBV-Associated Malignancies

Abstract

UN SDGs

Research Keywords

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Cite this